Rani Therapeutics Holdings, Inc. financial data

Symbol
RANI on Nasdaq
Location
2051 Ringwood Avenue, San Jose, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 7, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 113 % -72.8%
Debt-to-equity -3.59K % -1106%
Return On Equity 2.27K %
Return On Assets -98 % -80.7%

Shares

Label TTM Value / Value Unit Change %
Entity Public Float 51.9M USD -4.07%
Weighted Average Number of Shares Outstanding, Basic 36.5M shares +38.8%
Weighted Average Number of Shares Outstanding, Diluted 36.5M shares +38.8%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD
Research and Development Expense 25.1M USD -23%
General and Administrative Expense 21.7M USD -14.3%
Operating Income (Loss) -49.3M USD +14.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -67.9M USD -7.28%
Income Tax Expense (Benefit) 0 USD -100%
Net Income (Loss) Attributable to Parent -29.7M USD +2.93%
Earnings Per Share, Basic 0 USD/shares +23.7%
Earnings Per Share, Diluted 0 USD/shares +23.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 10.2M USD +126%
Accounts Receivable, after Allowance for Credit Loss, Current 600K USD
Assets, Current 11.1M USD -65.4%
Property, Plant and Equipment, Net 1.14M USD -79.9%
Operating Lease, Right-of-Use Asset 4.39M USD -23.7%
Other Assets, Noncurrent 293K USD +19.1%
Assets 16.9M USD -61.4%
Accounts Payable, Current 1.8M USD +255%
Liabilities, Current 20.6M USD +24.4%
Operating Lease, Liability, Noncurrent 3.2M USD -27.1%
Liabilities 26.1M USD -31.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax 3K USD
Retained Earnings (Accumulated Deficit) -117M USD -34.1%
Stockholders' Equity Attributable to Parent -5.58M USD -297%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -9.15M USD -265%
Liabilities and Equity 16.9M USD -61.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -8.15M USD +13.3%
Net Cash Provided by (Used in) Financing Activities -3.73M USD -3183%
Net Cash Provided by (Used in) Investing Activities 18.2M USD +77.1%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6.35M USD +527%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 10.7M USD +114%
Deferred Tax Assets, Valuation Allowance 69.1M USD +13.2%
Deferred Tax Assets, Gross 69.1M USD +13.2%
Operating Lease, Liability 4.39M USD -23.7%
Payments to Acquire Property, Plant, and Equipment 51K USD +183%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -30M USD +1.84%
Lessee, Operating Lease, Liability, to be Paid 5.25M USD -26.4%
Property, Plant and Equipment, Gross 5.87M USD +31.3%
Operating Lease, Liability, Current 1.19M USD -12.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.23M USD -35.4%
Lessee, Operating Lease, Liability, to be Paid, Year One 953K USD +2.47%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 860K USD -37.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.28M USD +3.99%
Deferred Tax Assets, Operating Loss Carryforwards 19.4M USD +49.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 20M shares 0%
Unrecognized Tax Benefits 661K USD +35.2%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.33M USD +4.07%
Operating Lease, Payments 473K USD +163%
Additional Paid in Capital 111M USD +23.6%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 3.93M USD +1.42%
Interest Expense 4.28M USD -17.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%